Ibrutinib-Rituximab and Venetoclax (IRV) Followed by Risk-Stratified R-HyperCVAD/MTX in Young Patients With Untreated Mantle Cell Lymphoma – Phase-II WINDOW-2 Trial

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    x